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Abstract
In humans, hepatic iron overload can lead to hepatocellular carcinoma development. Iron related dysregulation of hepatic
genes could play a role in this phenomenon. We previously found that the carbonyl-iron overloaded mouse was a useful
model to study the mechanisms involved in the development of hepatic lesions related to iron excess. The aim of the present
study was to identify hepatic genes overexpressed in conditions of iron overload by using this model. A suppressive
subtractive hybridization was performed between hepatic mRNAs extracted from control and 3% carbonyl-iron overloaded
mice during 8 months. This methodology allowed us to identify stearoyl coenzyme A desaturase 1 (SCD1) mRNA
overexpression in the liver of iron loaded mice. The corresponding enzymatic activity was also found to be significantly
increased. In addition, we demonstrated that both SCD1 mRNA expression and activity were increased in another iron
overload model in mice obtained by a single iron-dextran subcutaneous injection. Moreover, we found, in both models, that
SCD1 mRNA was not only influenced by the quantity of iron in the liver but also by the duration of iron overload since
SCD1 mRNA upregulation was not detected in earlier stages of iron overload. In addition, we found that cellular repartition
likely influenced SCD1 mRNA expression. In conclusion, we demonstrated that iron excess in the liver induced both the
expression of SCD1 mRNA and its corresponding enzymatic activity. The level and duration of iron overload, as well as
cellular repartition of iron excess in the liver likely play a role in this induction. The fact that the expression and activity of
SCD1, an enzyme adding a double bound into saturated fatty acids, are induced in two models of iron overload in mice leads
to the conclusion that iron excess in the liver may enhance the biosynthesis of unsaturated fatty acids. ß 2001 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Iron is crucial for cellular life. However, its excess
can induce organ damage. The liver, which is the
main iron storage site in the organism, is a speci¢c
target. During iron overload diseases, liver ¢brosis,
cirrhosis, and hepatocellular carcinoma are fre-
quently observed [1^5]. In addition, many authors
suggest that during alcoholic liver diseases and
0925-4439 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 0 1 ) 0 0 0 2 4 - 2
* Corresponding author. Fax: +33-2-99540137;
E-mail : christelle.pigeon@rennes.inserm.fr
BBADIS 62015 15-3-01
Biochimica et Biophysica Acta 1535 (2001) 275^284
www.bba-direct.com
chronic viral hepatitis, liver iron excess may exacer-
bate hepatic damage [6^9].
Molecular mechanisms involved in the develop-
ment of hepatic lesions in conditions of liver iron
excess are not well characterized. On the one hand,
it has been reported that high amounts of hepatic
iron increase the production of free radical hydroxyls
thereby inducing lipid and DNA peroxidation [10^
13]. On the other hand, it must also be considered
that expression of some hepatic genes may be in£u-
enced by liver iron overload, thereby leading to the
disturbance of biological or metabolic pathways. Un-
til now, only few mRNAs have been identi¢ed as
modulated by iron excess in the liver. It is well
known that the transferrin receptor mRNA steady-
state level is decreased during iron overload in the
liver due to the presence of an iron responsive ele-
ment in its 3P untranslated region [14^16]. In addi-
tion, in vivo and in vitro studies performed in exper-
imental models have reported an increase of
transforming growth factor L and procollagen I
mRNAs, both involved in the development of ¢bro-
sis, under the e¡ect of iron overload [17^19]. In in
vivo models of iron overload, it has been demon-
strated that the expression of Q-glutamyl transpepti-
dase [20] and heme oxygenase 1 [21], two proteins
potentially involved in oxidative stress, are also up-
regulated in the liver. Fimmel et al. [22] also reported
an increase in the amount of complement C4 mRNA
in hepatic stellate cells isolated from the liver of car-
bonyl-iron overloaded rats as compared to those iso-
lated from control rats.
Taking these data together, it appears that identi-
¢cation of hepatic genes modulated by iron excess is
crucial because they may participate in the develop-
ment of hepatic lesions related to iron excess in hu-
mans.
With this aim, we performed suppressive subtrac-
tive hybridization (SSH) between livers from iron
overloaded and control mice and studied hepatic
genes which were induced during iron overload.
This recently developed methodology allows the
analysis of di¡erential gene expression in two given
conditions [23]. Using this technology on the carbon-
yl-iron overloaded mouse model, we highlighted the
upregulation of stearoyl coenzyme A desaturase 1
(SCD1) mRNA, which encodes an enzyme involved
in lipid metabolism. This overexpression was con-
¢rmed in another model of iron overload in mice
using iron-dextran. In both models of iron overload,
we also found that the increase of SCD1 mRNA
expression was accompanied by an enhancement of
SCD1 activity.
2. Materials and methods
2.1. Animals
In this study, 5 week old BALB/cJ male mice were
used (CERJ, Le Genest St Isle, France). They were
maintained under standard conditions of light, at-
mosphere, and temperature according to French
law and regulations. They had free access to tap
water and standard AO3 diet (UAR, France). The
composition of the diet was 21, 5.5, and 51% of
proteins, lipids, and glucids respectively and the
iron content was 280 mg/kg of diet. The animals
were sacri¢ced by cervical dislocation. Livers were
removed immediately after sacri¢ce and conserved
as necessary for the di¡erent investigations. Iron
overload was performed using carbonyl-iron or
iron-dextran.
2.1.1. Carbonyl-iron overload
In a ¢rst set of experiments, mice were iron over-
loaded for 8 months by addition of 0.5, 1.5, or 3%
carbonyl-iron to the diet. Animals receiving no car-
bonyl-iron in the diet were used as controls. We have
previously characterized this model [24]. Liver iron
concentrations (LICs) in 3, 1.5, and 0.5% carbonyl-
iron supplemented mice were respectively on average
ten, four, and two times as high as the control value
[24].
In another similar experiment, 3% carbonyl-iron
was added to the diet for 2 or 8 months to con¢rm
the results and to study the relationship between du-
ration of iron overload and level of mRNA overex-
pression.
2.1.2. Iron-dextran overload
A single subcutaneous injection of iron-dextran
(Sigma, France) was performed at a dose of 1 g/kg
body weight on 5 week old mice as previously de-
scribed by Carthew et al. [25]. Control mice received
a single injection of a mixture containing dextran
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and phenol at the same concentration as in the iron-
dextran solution. Animals were sacri¢ced 4 months
later.
To study the e¡ect of iron overload duration on
SCD1 mRNA expression, animals were sacri¢ced
1 week, 3 weeks, or 2 months after iron-dextran in-
jection. Three animals were included in each group at
each point.
2.2. Histological study
For histological studies, livers were ¢xed in 4%
formalin, and para⁄n embedded thereafter. Slices
of liver (5 Wm) were stained using Perls’ staining
for iron assessment. Hepatic lobular and cellular lo-
calization of iron deposits has been reported for each
case on Perls’ stain using the total iron score (TIS)
[26,27]. TIS is the sum of HIS (hepatocytic iron
score), SIS (sinusoidal iron score), and PIS (portal
iron score). HIS re£ects the quantity of iron depos-
ited in hepatocytes, whereas SIS re£ects the quantity
of iron deposited in sinusoidal cells. Finally, PIS re-
£ects the presence of iron in the portal space, includ-
ing extracellular space, biliary canals, and endothelial
cells.
2.3. Hepatic iron concentration
LIC was evaluated biochemically from livers pre-
viously ¢xed in 4% formalin according to Barry and
Sherlock’s method [28].
2.4. Total RNAs and poly(A)+ RNA extraction
Total RNAs were extracted from each liver speci-
men previously frozen in liquid nitrogen using the
Promega kit SV total RNA isolation system (Madi-
son, WI, USA). To perform the SSH, total RNAs
were pooled for each group of mice and poly(A)
RNAs were generated (Invitrogen’s FastTract kit).
2.5. Suppressive subtractive hybridization
SSH was performed using the PCR-Select cDNA
Subtraction kit (Clontech, Palo Alto, CA, USA) ac-
cording to the manufacturer’s instructions. Brie£y,
double strand cDNAs were prepared from 2 Wg of
poly(A) RNAs from livers of control mice (n = 4)
(driver population) and 3% carbonyl-iron overloaded
mice (n = 4) (tester population). The cDNAs were
then digested with RsaI. Tester cDNA was ligated
to adapter 1 and to adapter 2 in two separate liga-
tions. In the ¢rst hybridization, excess of driver
cDNA was ¢rstly hybridized for 8 h at 68‡C with
tester cDNA ligated to adapter 1 in reaction 1 and
with cDNA ligated to adapter 2 in reaction 2. Sec-
ondly, reactions 1 and 2 were hybridized together in
the presence of fresh driver cDNA. This second hy-
bridization was performed overnight at 68‡C. The
subtractive product was ampli¢ed by PCR using oli-
gonucleotides which were complementary to adapters
1 and 2 respectively. PCR was performed according
to the following parameters: 75‡C for 5 min; 27
cycles at (94‡C for 30 s; 66‡C for 30 s; 72‡C for
1.5 min). Then, a nested PCR was performed as fol-
lows: 12 cycles at (94‡C for 30 s; 68‡C for 30 s; 72‡C
for 1.5 min). The ¢nal PCR product was named iron
induced cDNAs and corresponded to the gene pop-
ulation overexpressed in the liver by iron excess. In
the same manner, we performed the reverse subtrac-
tive hybridization in order to obtain genes repressed
in the liver by iron excess. This ¢nal product was
named iron repressed cDNA.
2.6. Cloning and selection of iron induced cDNAs
Iron induced cDNAs obtained from the nested
PCR were cloned into a T/A pCR 2.1 plasmid (The
Ligator, RpD Systems, Wiesbaden-Nordenstadt,
Germany). Transformation e⁄ciency was approxi-
mately 107 colonies per Wg of starting DNA. Five
thousand clones were plated onto LB selection me-
dium plates. Replicas were performed on nitrocellu-
lose ¢lters and prepared for hybridization. Iron in-
duced cDNAs and iron repressed cDNAs were
labeled with [K-32P]dCTP (3000 Ci/mmol, Amer-
sham, Buckinghamshire, UK) using the Rediprime
II kit (Amersham). Filters were successively hybrid-
ized with labelled iron induced cDNAs and following
dehybridization, with labelled iron repressed cDNAs.
Filters were then autoradiographed and stored at
380‡C. Di¡erentially expressed clones were selected
by comparing and overlaying autoradiograms ob-
tained with the two probes. Clones that showed little
or no detectable hybridization with the iron re-
pressed cDNA probe but a strong hybridization
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with the iron induced cDNA probe were isolated.
Clones which hybridized similarly with the two
probes were considered false positives and were elim-
inated. Following the initial screening, selected clones
were picked up onto a new LB selection plate and
transferred onto new nitrocellulose ¢lters. A second
round of selection was then performed as described
above. Finally, the two rounds of selection allowed
us to identify 150 clones which were potentially in-
duced by iron. Plasmids from selected colonies were
puri¢ed using the Wizard PCR Preps DNA puri¢ca-
tion system (Promega, Madison, WI, USA). Fifty
randomly selected clones were sequenced using the
Thermosequenase kit (Amersham, Buckinghamshire,
UK) with K-33P radiolabelled dideoxynucleotides
(1500 Ci/mmol). Samples were analyzed on a 5%
polyacrylamide urea gel. DNA identity scores were
generated by matching the query sequences to a sub-
ject found in the GenBank and EMBL databases
using the BLAST algorithm. Seven di¡erent cDNAs
were identi¢ed.
2.7. RNA blot analysis
Total liver RNAs (10 Wg) were loaded on a dena-
turing 1.2% agarose gel and then transferred to Hy-
bond N ¢lters (Amersham, Buckinghamshire, UK).
Filters were hybridized with selected [K-32P]dCTP
(3000 Ci/mmol) radiolabelled cDNAs (Rediprime
II, Amersham, Buckinghamshire, UK). Filters were
autoradiographed and stored at 380‡C. The quanti-
¢cation of mRNA abundance was performed by den-
sitometry and lane loading di¡erences were measured
using a L-actin probe. The mouse cytoskeletal L-actin
cDNA (GenBank accession number X03672) used in
this study was generated by RT-PCR using oligonu-
cleotides 5P-TGTGCTGTCCCTGTATGCCT-3P and
5P-TAGGAGCCAGAGCAGTAATC-3P. The gener-
ated cDNA fragment was 553 bp in length.
2.8. Stearoyl coenzyme A desaturase 1 activity assay
Fresh livers from each mouse overloaded with 3%
carbonyl-iron for 8 months and each mouse over-
loaded with iron-dextran (sacri¢ced 4 months later)
were homogenized in four volumes of a solution of
0.25 M sucrose and 50 mM phosphate bu¡er (pH
7.4) [29]. Livers from the respective control mice
were processed identically. The solution was then
centrifuged at 10 000Ug for 10 min. An aliquot of
the supernatant was stored at 320‡C for protein
measurement. The supernatant was used as the enzy-
matic solution for the stearoyl coenzyme desaturase 1
assay, and incubated at 37‡C in the presence of coen-
zyme A (0.54 mM), ATP (7.2 mM), NADH (0.8
mM), MgCl2 (6 mM), and phosphate bu¡er (102
mM, pH 7.16). The reaction was initiated by the
addition of 30 nmol [14C]stearic acid (440 GBq/
mol) in 3 Wl ethanol and stopped 20 min later by
adding 2 mmol KOH in ethanol. Each assay mixture
was heated 30 min at 70‡C. The fatty acids were
liberated by acidi¢cation, extracted with diethylether
and dried. Fatty acid methyl esters were prepared by
heating at 70‡C for 30 min with a methanol:H2SO4
(10:1, v/v) solution and then extracted with pentane.
They were later separated by thin layer chromatog-
raphy on silver nitrate impregnated silica gel H
(12 g/100 g) plates using a mixture of diethylether:
hexane (10:90, v/v). Spots corresponding to the sub-
strate stearic acid and product oleic acid were visu-
alized by dichloro£uorescein and radioactivity was
counted (Packard Tri-carb 1600 TR, Meriden, CT,
USA). Enzymatic activity was determined from the
amount of radioactivity and expressed as nmol stea-
ric acid converted to oleic acid/min/mg protein. Pro-
tein concentration was determined by a modi¢ed
Lowry procedure [30] in the supernatant described
above.
2.9. Statistical analysis
Results were expressed as mean þ S.D. The Mann^
Whitney test was used for the estimation of statistical
signi¢cance when appropriate. A P value less than
0.05 was considered statistically signi¢cant.
3. Results
3.1. Identi¢cation of hepatic overexpression of SCD1
mRNA in carbonyl-iron overloaded mice
Performing SSH between cDNAs from the liver of
3% carbonyl-iron overloaded mice and control mice,
we isolated a cDNA of 338 bp. A query of the Gen-
Bank database using the BLAST algorithm revealed
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that this cDNA was 100% identical in its overlapping
region to exon 6 of SCD1 (GenBank accession num-
ber M21285), also named delta 9 desaturase, an en-
zyme of lipid metabolism. Six other cDNAs were
also identi¢ed. Preliminary Northern blot analysis
showed that the mRNA overexpression was clear
only for two of them including SCD1 mRNA and
an mRNA that we cloned and characterized sepa-
rately [31]. In addition, as some data of the literature
suggested a link between iron and lipid metabolisms,
we decided to further study the relationship between
iron overload and SCD1 mRNA expression.
Fig. 1. SCD1 expression in carbonyl-iron overloaded mice. (A) Expression of SCD1 mRNA analyzed by Northern blot in livers of
mice overloaded with 0.5, 1.5, and 3% carbonyl-iron for 8 months and control mice. Each lane corresponds to one animal. SCD1
mRNA was greatly overexpressed in the liver of iron overloaded mice. Hybridization with the L-actin probe is also presented in order
to evaluate lane loading di¡erences. LICs expressed as Wmol/g of dry liver are mentioned. (B) Densitometry analysis of the autoradio-
graphs. The average for each group of iron overload is presented in histograms (white bars: actin; gray bars: SCD1 mRNAs). Densi-
tometry values obtained in control mice were arbitrarily expressed as 100% for each mRNA. Statistical analysis is reported as
*P6 0.05 and **P6 0.01 between overloaded mice and control mice. (C) SCD1 activity measured in the livers of iron overloaded
mice with 3% carbonyl-iron for 8 months (n = 6) and their controls (n = 6).
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In order to con¢rm SCD1 mRNA overexpression
in the liver of mice overloaded with 3% carbonyl-iron
for 8 months, Northern blot analysis was performed
using SCD1 cDNA, obtained by SSH, as a probe.
Moreover, mRNA expression was analyzed in the
liver of mice fed intermediate doses of carbonyl-iron
(0.5 and 1.5%) to search for a possible dose depen-
dent expression of SCD1 mRNA. As presented in
Fig. 1A, the SCD1 probe hybridized with a 5 kb
mRNA. This length corresponded to the expected
size of SCD1 mRNA. In the liver of carbonyl-iron
overloaded mice, the SCD1 mRNA amount was in-
creased in a dose dependent manner. Its expression
was maximal in the livers of 3% carbonyl-iron over-
loaded mice. It was indeed 6.1 fold more than in
control mice which had a carbonyl-iron free diet
(Fig. 1B). Despite the fact that the level of SCD1
mRNA was heterogeneous from one mouse to an-
other one, this overexpression was statistically signif-
icant (Fig. 1B; P6 0.01).
Therefore, we measured SCD1 activity to see if the
upregulation of SCD1 mRNA, observed in the livers
of iron overloaded mice, was associated with an en-
hancement of SCD1 enzymatic activity. This inves-
tigation was performed on livers obtained from mice
overloaded with 3% carbonyl-iron for 8 months for
which we found SCD1 mRNA induction. Assays
demonstrated a 3.3 fold increase of SCD1 activity
in the liver of 3% carbonyl-iron overloaded mice as
compared to control mice (Fig. 1C). This increase
was statistically signi¢cant (P6 0.01).
3.2. Overexpression of SCD1 mRNA in the liver of
iron-dextran overloaded mice
In order to determine whether the overexpression
of SCD1 mRNA was e¡ectively related to iron excess
and not to other nutritional disturbances induced by
oral carbonyl-iron supplementation, we analyzed
SCD1 mRNA expression in another in vivo model
of iron overload in mice using iron-dextran injection.
In these animals, which were sacri¢ced 4 months
after the injection, we found a 3 fold increase of
SCD1 mRNA steady-state level as compared to con-
trol mice (P6 0.01; Fig. 2A,B). In these mice, the
LIC was 21 fold higher in iron-dextran treated
mice than in control mice (165.4 þ 30.3 versus
7.8 þ 0.8 Wmol iron/g dry weight, respectively). The
overexpression of SCD1 mRNA was associated with
a 2.8 fold (P6 0.02) increase of SCD1 enzymatic
activity in the liver of iron-dextran mice compared
to control mice (Fig. 2C).
Fig. 2. SCD1 expression in iron-dextran overloaded mice. (A)
Hepatic expression of SCD1 mRNA in livers of iron-dextran
injected mice (n = 5) and control mice (n = 4). SCD1 mRNA
was upregulated by iron excess whereas L-actin mRNA was
not. LICs expressed as Wmol/g of dry liver are mentioned. (B)
The average densitometry of autoradiographs is presented in
histograms (white bars: actin; gray bars: SCD1). Densitometry
values obtained in control mice were arbitrarily expressed as
100% for each mRNA. Statistical analysis is reported as
*P6 0.01 between overloaded mice and control mice. (C) SCD1
activity (delta 9 desaturase) measured in the livers of 4 months
iron-dextran overloaded mice (n = 5) and their controls (n = 4).
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3.3. In£uence of iron overload duration and hepatic
cellular repartition of iron excess on SCD1
mRNA expression
Then, we studied the expression of SCD1 mRNA
at earlier stages of iron overload for both models.
For the carbonyl-iron overload model, when iron
was administered for only 2 months, the amount of
SCD1 mRNA was quite identical in the liver of con-
trol mice and mice fed 3% carbonyl-iron although
the LIC was 14 fold higher in the latter group (Table
1). After 8 months, corresponding to a LIC of the
order of 120 Wmol iron/g dry tissue in iron over-
loaded mice, SCD1 mRNA induction was similar
to that observed in animals used for SSH. Then,
to compare iron repartition in the liver at 2 and
8 months, we evaluated iron deposits in hepatic cells
using histological iron scores. We observed that TIS
increased concomitantly with LIC. In addition the
rise of the PIS/TIS ratio and the drop of the HIS/
TIS ratio re£ect that the relative weights of portal
and hepatocytic iron deposits in the TIS calculation
respectively increased and decreased between 2 and
8 months (Table 1). Thus, the carbonyl-iron model
after 2 and 8 months di¡ers in terms of both liver
iron load and hepatic cellular repartition of iron ex-
cess.
In the iron-dextran model, despite the fact that the
SCD1 mRNA level was not signi¢cantly modi¢ed
between 1 and 3 weeks after iron injection, its
steady-state level was clearly increased in iron treated
mice which were sacri¢ced 2 months after the injec-
tion. In this model, LIC and TIS reached a plateau
as soon as 1 week. However, there was a progressive
rise of the HIS/TIS ratio and a concomitant decrease
of the SIS/TIS ratio (Table 2). These data mean that,
Table 1
Study of SCD1 mRNA expression and corresponding iron load parameters in carbonyl-iron overloaded mice
2 months 8 months
control, n = 4 iron loaded, n = 4 control, n = 4 iron loaded, n = 4
SCD1 mRNA level 100 þ 80 110 þ 70 100 þ 98 320 þ 80*
LIC 5.5 þ 1 72 þ 9 10.5 þ 1 120 þ 20**
TIS 0 þ 0 15.3 þ 1.9 1.8 þ 2.3 22.5 þ 1.7**
HIS/TIS nc 60 þ 7 nc 43 þ 3**
SIS/TIS nc 21 þ 1 nc 25 þ 3
PIS/TIS nc 19 þ 6 nc 32 þ 1**
SCD1 mRNA is expressed as 100% of the control values obtained at the same time. LIC is expressed as Wmol iron/g dry weight liver.
TIS, which is the sum of the HIS, SIS, and PIS, is expressed in arbitrary units. HIS, SIS, and the ratio PIS/TIS are expressed as per-
centages. *Signi¢cantly di¡erent from the control value obtained at the same time. **A signi¢cant increase or decrease of the corre-
sponding parameter was observed in the iron loaded group. nc = not calculated (TIS = 0).
Table 2
Study of SCD1 mRNA expression and corresponding iron load parameters in iron-dextran overloaded mice
1 week 3 weeks 2 months
control, n = 3 iron loaded, n = 3 control, n = 3 iron loaded, n = 3 control, n = 3 iron loaded, n = 3
SCD1 mRNA 100 þ 38 110 þ 42 100 þ 91 213 þ 106 100 þ 98 402 þ 100*
LIC 5.6 þ 0.8 198 þ 51 5.7 þ 1.2 211 þ 24 6 þ 1 177 þ 8
TIS 0 þ 0 17 þ 4.1 0 þ 0 22.5 þ 1.7 0 þ 0 21 þ 0
HIS/TIS nc 28 þ 7 nc 40 þ 4** nc 57 þ 0**
SIS/TIS nc 56 þ 2 nc 40 þ 2** nc 24 þ 0**
PIS/TIS nc 16 þ 7 nc 20 þ 3 nc 19 þ 0
SCD1 mRNA is expressed as 100% of the control values obtained at the same time. LIC is expressed as Wmol iron/g dry weight liver.
TIS, which is the sum of the HIS, SIS, and PIS, is expressed in arbitrary units. HIS, SIS, and the ratio PIS/TIS are expressed as per-
centages. *Signi¢cantly di¡erent from the control value obtained at the same time. **A signi¢cant increase or decrease of the corre-
sponding parameter was observed in the iron loaded group. nc = not calculated (TIS = 0).
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in this model, iron content is stable over time, but
iron repartition varies with, respectively, an increase
and a drop of hepatocytic and sinusoidal iron depos-
its.
4. Discussion
Mechanisms involved in the development of hepat-
ic ¢brosis and hepatocellular carcinoma during iron
overload diseases in humans are not well understood.
We hypothesized that abnormal expression of some
hepatic genes during iron overload may be involved
in these phenomena.
In a previous work we characterized a new murine
model of hepatic iron overload obtained by supple-
mentation of 3% carbonyl iron in the diet [24]. This
model exhibited a strong iron overload of the liver
associated with the following hepatocyte nuclear ab-
normalities: (i) presence of iron containing ferritin
inclusions, (ii) enlargement of hepatocyte nucleus
size, and (iii) increase of mitotic index with presence
of abnormal mitotic ¢gures, particularly well estab-
lished after 12 months of iron exposure. In addition,
some iron free hepatocyte foci were found. Except
for their smaller size, they were comparable to iron
free foci found in humans during genetic hemochro-
matosis which could predict hepatocellular carcino-
ma development [32]. Taking these data together, we
concluded that this murine iron overload model was
useful to study the molecular mechanisms involved in
the development of hepatic lesion related to iron ex-
cess, especially hepatocellular carcinoma.
In order to identify hepatic genes abnormally over-
expressed during iron overload and possibly involved
in the development of hepatic lesions, we performed
SSH between cDNAs obtained respectively from the
livers of control and 8 months 3% carbonyl-iron
overloaded mice. This method allowed us to identify
an increase of the SCD1 mRNA steady-state level in
carbonyl-iron overloaded mice as compared to con-
trol mice. SCD1 mRNA encodes the ¢rst enzyme
involved in fatty acid desaturation meaning biosyn-
thesis of unsaturated fatty acids [33]. This process
mainly occurs in the liver. Since recent observations
obtained in humans suggest interactions between
iron and lipid metabolisms [34] we decided to further
study the relationship between liver iron excess and
both SCD1 mRNA expression and activity. This en-
zyme is part of an enzymatic complex including cy-
tochrome b5 reductase and cytochrome b5 in addi-
tion to the SCD1 enzyme [33]. This complex
catalyzes the oxidative conversion of stearoyl coen-
zyme A, a saturated fatty acid, to oleyl coenzyme A
by adding a double bond between carbons 9 and 10
of stearoyl coenzyme A. Concerning SCD1, it has
been previously demonstrated that SCD1 mRNA ex-
pression can be modulated by many factors. Indeed,
it is well known that SCD1 expression can be in-
creased by insulin [35,36], fructose [35], glucose
[37], a lipid poor diet [38], and peroxisome prolifer-
ators [39]. Conversely, polyunsaturated fatty acids
and glucagon were able to decrease the mRNA level
[36,40]. In our work, we found a large amount of
SCD1 mRNA in the livers of mice which were over-
loaded with 3% carbonyl-iron for 8 months as com-
pared to control mice. This result suggests that iron
excess is another factor which is able to modulate
SCD1 mRNA expression.
To con¢rm the role of iron itself in the mRNA
overexpression, we used another model of iron over-
load in mice using iron-dextran injection. By using
the parenteral route, we aimed to avoid any indirect
mechanisms of upregulation due to possible distur-
bance in nutrient absorption, related to the oral
loading with carbonyl-iron. We clearly observed an
increase of the SCD1 mRNA steady-state level in
parenterally iron overloaded animals at 2 months
as well as 4 months after iron injection, thereby sug-
gesting that iron excess itself is responsible for the
overexpression. This result was reinforced by the in-
duction of the SCD1 mRNA in an iron dose depen-
dent manner when carbonyl-iron was administered
for 8 months.
Then, we con¢rmed that the increase in the
mRNA level was associated with a rise of the corre-
sponding SCD1 activity in the livers of mice over-
loaded with carbonyl-iron or iron-dextran. In addi-
tion to the ability of iron to control SCD1 mRNA
expression that we highlighted in this paper, it has
been previously demonstrated that the activity of
SCD1 can also be modulated at the post-translation-
al level by iron status. Indeed, it is well established
that SCD1 is an enzyme containing one iron atom
[41] and that its activity is decreased in situations of
cellular iron deprivation induced by iron chelation
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[42,43]. However, the mechanism involved in the
SCD1 mRNA overexpression in the livers of iron
loaded animals is not known. Considering that, in
the iron-dextran model, the SCD1 mRNA steady-
state level increases only a few weeks after the injec-
tion, whereas LIC rises quickly (a few days) it is
unlikely that the e¡ect of iron on SCD1 expression
and activity is a direct one. This view may be sup-
ported by the fact that we did not ¢nd an overex-
pression of SCD1 mRNA in mouse hepatocytes ex-
posed to citrate iron (data not shown). Conversely, it
is likely that the development of liver iron overload is
able to induce cellular or biochemical alterations
which in turn could lead to and/or participate in
the SCD1 mRNA overexpression. In such a case,
SCD1 mRNA overexpression could re£ect a com-
pensatory mechanism in response to a cellular need
for renewing unsaturated fatty acids. Indeed, it has
been reported in di¡erent in vivo models of iron
overload that hepatic iron excess usually results in
hepatic lipid peroxidation meaning unsaturated fatty
acid degradation [44^46].
In order to study if SCD1 mRNA expression is
enhanced at early stages of iron overload, we per-
formed di¡erent durations of overload for both car-
bonyl-iron and iron-dextran models. We found that
in the carbonyl-iron model, the induction was late
(after 8 months of iron exposure), occurring when
LIC was very high (120 Wmol iron/g dry tissue).
However, from data obtained in the iron-dextran
model, it is clear that a strong iron amount in the
liver was not su⁄cient to lead to SCD1 mRNA in-
duction. Indeed, in this model, even though the LIC
found 1 week after the injection was higher than that
found after 8 months of carbonyl-iron supplementa-
tion, no upregulation of SCD1 mRNA was found at
this time. Nevertheless, SCD1 mRNA overexpression
was found 2 months after iron injection whereas LIC
was quite similar to that measured after 1 week. We
therefore propose that other factor(s) may in£uence
the expression of SCD1 mRNA. In the carbonyl-iron
model, it is well established that iron deposits are
mainly located in hepatocytes [24,47], whereas in
the iron dextran model iron deposits are mainly lo-
cated in non-parenchymal cells in the earlier stages of
iron overload [25]. In this latter model, there is a
modi¢cation of cellular hepatic iron repartition
over time. Indeed, we observed an increase of the
HIS/TIS ratio concomitant with a decrease of the
SIS/TIS ratio. Thus, a change of iron repartition in
the liver in addition to a high LIC likely participates
in SCD1 overexpression during iron overload. Anal-
ysis of the data showed that, for the two models,
SCD1 mRNA overexpression was observed only
when the HIS/TIS ratio was higher than 40% sug-
gesting that abundant and prolonged iron deposits in
hepatocytes are required for the overexpression of
SCD1 mRNA. Such features of iron deposits are
observed in human pathology.
In conclusion, performing SSH, we demonstrated
that the SCD1 mRNA level and its corresponding
enzymatic activity were increased in chronically car-
bonyl-iron and iron-dextran overloaded mice. The
level of iron overload in the liver and the hepatic
cellular types involved in the storage of iron excess
are both likely to play a role. By in£uencing SCD1
expression and activity, iron excess in the liver may
enhance the biosynthesis of unsaturated fatty acids.
The disturbance of this metabolic pathway could
play a role in the development of hepatic injuries
triggered by iron excess.
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